The article discusses the highlights of the clinical trial FOURIER, which assessed the efficacy of evolocumab, a human monoclonal antibody when given along with statin therapy, can improve outcomes among high-risk cardiovascular patients . Study Background For the past couple of years, cardiologists and experts have been discussing the merits of evolocumab and alirocumab, that were approved by FDA in 2015 for the treatment of high cholesterol. The approval was given based on its capacity to lower the low-density cholesterol (LDL) remarkably, however, without any major clinical trial.
Hence it was necessary to pursue further study to test whether the evolocumab improve outcomes in the clinical trial. Evolocumab is a human monoclonal antibody that has shown to reduce the LDL cholesterol levels by 60%. Genetic studies show that this antibody blocks the proprotein convertase…
